New Drug Reduces Heart Attack Risk

Evolocumab reduces heart attack risk by 20% in high-risk patients with atherosclerosis or diabetes, lowering mortality rates effectively.

Myasthenia Gravis survival is better than Multiple Sclerosis in new data. Patients with MG live 15 to 19…

FDA approves rusfertide (Mimrylo) for erythrocytosis, sparing polycythemia vera patients from painful phlebotomies. Read the latest medical news.

The DOJ drops the Olmstead defense in Texas v. Kennedy, shifting from defending HHS rules to siding with…

New study reveals significant weight loss outcomes with up to 16.6% mean weight loss and reduced liver fat…

Learn about a new three-stage framework for early arthritis detection designed to identify psoriatic joint damage before permanent…

A new AACR Lung Cancer Task Force roadmap outlines key research priorities to close the survival gap and…

CAR T cell therapy gets new guidelines to protect patients and ensure safe delivery, reflecting advancements in the…

Rural patients face gaps in hospice access and care intensity compared to urban settings. Learn how Medicare hospice…

FDA approves new narcolepsy treatment targeting orexin deficiency for narcolepsy type 1 patients.